IXHL vs. IMAB, BPTS, RGLS, CRVO, CAPR, SYRS, SGMT, AMLX, ANVS, and VTGN
Should you be buying Incannex Healthcare stock or one of its competitors? The main competitors of Incannex Healthcare include I-Mab (IMAB), Biophytis (BPTS), Regulus Therapeutics (RGLS), CervoMed (CRVO), Capricor Therapeutics (CAPR), Syros Pharmaceuticals (SYRS), Sagimet Biosciences (SGMT), Amylyx Pharmaceuticals (AMLX), Annovis Bio (ANVS), and Vistagen Therapeutics (VTGN). These companies are all part of the "pharmaceutical preparations" industry.
Incannex Healthcare (NASDAQ:IXHL) and I-Mab (NASDAQ:IMAB) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, dividends, analyst recommendations, valuation, community ranking, earnings and media sentiment.
In the previous week, Incannex Healthcare had 2 more articles in the media than I-Mab. MarketBeat recorded 2 mentions for Incannex Healthcare and 0 mentions for I-Mab. Incannex Healthcare's average media sentiment score of 0.59 beat I-Mab's score of 0.00 indicating that Incannex Healthcare is being referred to more favorably in the media.
Incannex Healthcare has higher earnings, but lower revenue than I-Mab.
Incannex Healthcare has a beta of 8.69, meaning that its stock price is 769% more volatile than the S&P 500. Comparatively, I-Mab has a beta of 1.11, meaning that its stock price is 11% more volatile than the S&P 500.
I-Mab has a consensus target price of $12.25, suggesting a potential upside of 578.67%. Given I-Mab's higher possible upside, analysts plainly believe I-Mab is more favorable than Incannex Healthcare.
0.4% of Incannex Healthcare shares are held by institutional investors. Comparatively, 38.4% of I-Mab shares are held by institutional investors. 14.6% of Incannex Healthcare shares are held by insiders. Comparatively, 22.1% of I-Mab shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
I-Mab received 56 more outperform votes than Incannex Healthcare when rated by MarketBeat users.
Summary
I-Mab beats Incannex Healthcare on 6 of the 11 factors compared between the two stocks.
Get Incannex Healthcare News Delivered to You Automatically
Sign up to receive the latest news and ratings for IXHL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IXHL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Incannex Healthcare Competitors List
Related Companies and Tools
